EUPRAXIA PHARMACEUTICALS INC. (EPRX) Return on equity 2023–2025
EUPRAXIA PHARMACEUTICALS INC. (EPRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.0%FY2025 · since FY2023: -1273.4% → -47.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.0% | +29.3 pp |
| FY2024 | -76.3% | +1197.0 pp |
| FY2023 | -1273.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More EPRX financial trends
EPRX RevenueEPRX Net incomeEPRX Net marginEPRX Gross profitEPRX Gross marginEPRX Operating incomeEPRX Operating marginEPRX Operating cash flowEPRX Free cash flowEPRX Capital expendituresEPRX Stock buybacksEPRX Dividends paidEPRX Total assetsEPRX Total liabilitiesEPRX Shareholders’ equityEPRX overview →